ABT

Company financials

Abbott Laboratories

Health Care Health Care Equipment North Chicago, Illinois Last filing Feb 20, 2026 · FY2025

                    Revenue
                    FY2025
                
$44.3B
                    3y CAGR +0.5%
                    
                    P19
                    
                    +5.7%
                    
                    Net income
                    FY2025
                
$6.5B
                    Net margin +14.7%
                    
                    P67
                    
                    -51.3%
                    
                    Total assets
                    FY2025
                
$86.7B
                    ROA +7.5%
                    
                    P62
                    
                    +6.5%
                    
                    Operating cash flow
                    FY2025
                
$9.6B
                    FCF margin +16.7%
                    
                    P57
                    
                    +11.8%

19 yrs · FY2007–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

25 accounts · 5 years

Total assets $86.7B

Total liabilities $16.5B

Shareholders equity $52.1B

Account	2025	2024	2023	2022	2021
Assets
Cash and Cash Equivalents	19.2%	18.2%	17.2%	22.6%	22.7%
Short Term Investments	0.9%	0.8%	1.0%	0.7%	1.0%
Accounts Receivable	17.9%	16.5%	16.4%	14.2%	15.1%
Inventory	14.6%	14.8%	16.4%	14.1%	12.0%
Total Current Assets	58.6%	56.4%	56.5%	57.8%	56.3%
Property,Plant and Equipment	26.7%	25.4%	25.3%	21.0%	20.8%
Goodwill	54.2%	55.1%	59.0%	52.2%	53.9%
Intangible Assets	12.5%	15.8%	22.0%	23.9%	29.6%
Long Term Investments	2.1%	2.1%	2.0%	1.8%	1.9%
Total Assets	195.6%	194.1%	182.5%	170.5%	174.6%
Liabilities
Accounts Payable	9.6%	10.0%	10.7%	10.6%	10.2%
Accrued Liabilities	13.1%	12.3%	13.5%	13.4%	12.0%
Current Portion of Long Term Debt	6.8%	3.6%	2.7%	5.2%	1.8%
Total Current Liabilities	37.2%	33.7%	34.5%	35.5%	30.4%
Long Term Debt	22.3%	30.1%	33.9%	33.3%	40.2%
Other Noncurrent Liabilities	0.0%	8.2%	8.6%	8.7%	4.4%
Total Liabilities	37.2%	33.7%	34.5%	35.5%	30.4%
Equity
Preferred Stock	0.0%	0.0%	0.0%	0.0%	0.0%
Common Stock	57.6%	60.0%	62.0%	56.6%	56.8%
Retained Earnings	112.3%	112.7%	93.6%	80.8%	73.2%
Treasury Stock	38.7%	40.2%	39.8%	34.9%	27.4%
Accumulated Other Comprehensive Income	-13.5%	-18.8%	-19.5%	-18.4%	-19.4%
Noncontrolling Interest	1.4%	0.6%	0.6%	0.5%	0.5%
Total Stockholders Equity	117.6%	113.6%	96.2%	84.0%	83.1%
Total Liabilitiesand Equity	195.6%	194.1%	182.5%	170.5%	174.6%

Income Statement

Revenue, expense, and profitability

19 accounts · 5 years

Revenue $44.3B

Operating income $8.1B

Net income $6.5B

Account	2025	2024	2023	2022	2021
IncomeStatement
Revenues Total Revenue	100.0%	100.0%	100.0%	100.0%	100.0%
Expenses Cost of Revenue	43.6%	44.6%	44.8%	43.9%	43.0%
Expenses Research and Development	6.6%	6.8%	6.8%	6.6%	6.4%
Expenses Selling,General and Administrative	27.8%	27.9%	27.3%	25.8%	26.3%
Expenses Depreciation and Amortization	3.8%	4.5%	4.9%	4.6%	4.8%
Expenses Share Based Compensation	1.5%	1.6%	1.6%	1.6%	1.5%
Expenses Operating Expenses	81.8%	83.7%	83.8%	80.8%	80.4%
Other Income Expense Operating Income	18.2%	16.3%	16.2%	19.2%	19.6%
Other Income Expense Interest Income	0.7%	0.8%	1.0%	0.4%	0.1%
Other Income Expense Interest Expense	1.1%	1.3%	1.6%	1.3%	1.2%
Other Income Expense Other Income/expense	1.2%	0.9%	1.2%	0.7%	0.6%
Other Income Expense Income Before Tax	19.1%	16.7%	16.6%	19.0%	19.1%
Income Tax Income Tax Expense	4.4%	-15.2%	2.3%	3.1%	2.6%
net Income net Income	14.7%	31.9%	14.3%	15.9%	16.4%
net Income Comprehensive Income	19.0%	31.8%	14.8%	16.6%	17.7%
Earnings Per Share Basic Eps	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Diluted Eps	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Weighted Average Shares Basic	3.9%	4.1%	4.3%	4.0%	4.1%
Earnings Per Share Weighted Average Shares Diluted	3.9%	4.2%	4.4%	4.0%	4.2%

Cash Flow Statement

Operating, investing, and financing flows

19 accounts · 5 years

Operating cash flow $9.6B

Investing cash flow $-2.4B

Financing cash flow $-6.3B

Account	2025	2024	2023	2022	2021
CashFlow
Operating Activities net Income	14.7%	31.9%	14.3%	15.9%	16.4%
Operating Activities Depreciation and Amortization	3.2%	3.2%	3.2%	2.9%	3.5%
Operating Activities Stock Based Compensation	1.5%	1.6%	1.6%	1.6%	1.5%
Operating Activities Deferred Income Taxes	1.0%	-19.0%	-1.1%	-1.5%	-1.2%
Operating Activities Changes In Operating Assets and Liabilities	4.0%	3.7%	2.8%	3.6%	2.7%
Operating Activities net Cash From Operating Activities	21.6%	20.4%	18.1%	21.9%	24.5%
Investing Activities Capital Expenditures	4.9%	5.3%	5.5%	4.1%	4.4%
Investing Activities Purchases of Investments	0.4%	0.4%	0.4%	0.4%	0.4%
Investing Activities Other Investing Activities	-0.0%	-0.0%	-0.1%	-0.1%	-0.1%
Investing Activities net Cash From Investing Activities	-5.5%	-5.6%	-7.8%	-4.0%	-4.7%
Financing Activities Repurchase of Common Stock	2.0%	3.1%	3.1%	8.7%	5.3%
Financing Activities Dividends Paid	9.3%	9.1%	8.9%	7.6%	7.4%
Financing Activities Proceeds From Stock Issuance	0.9%	0.6%	0.4%	0.4%	0.6%
Financing Activities Other Financing Activities	-0.2%	0.0%	0.0%	0.0%	0.0%
Financing Activities net Cash From Financing Activities	-14.2%	-12.9%	-17.7%	-17.5%	-12.8%
Cash Reconciliation Effect of Exchange Rate On Cash	19.2%	18.2%	17.2%	22.6%	22.7%
Cash Reconciliation net Change In Cash	2.0%	1.7%	-7.4%	0.2%	6.9%
Cash Reconciliation Cash At Beginning of Period	19.2%	18.2%	17.2%	22.6%	22.7%
Cash Reconciliation Cash At End of Period	19.2%	18.2%	17.2%	22.6%	22.7%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 5 years

Ratio	2025	2024	2023	2022	2021
Profitability
Gross margin	+56.4%	+55.4%	+55.2%	+56.1%	+57.0%
Operating margin	+18.2%	+16.3%	+16.2%	+19.2%	+19.6%
Net margin	+14.7%	+31.9%	+14.3%	+15.9%	+16.4%
FCF margin	+16.7%	+15.1%	+12.6%	+17.9%	+20.1%
Growth
Revenue CAGR (3y)	+0.5%	-0.9%	+5.0%	+11.0%	+12.1%
Returns
ROE	+12.5%	+28.1%	+14.8%	+18.9%	+19.8%
ROA	+7.5%	+16.5%	+7.8%	+9.3%	+9.4%
ROIC	+11.0%	+12.6%	+12.0%	+16.0%	+16.5%
Liquidity
Current ratio	1.58x	1.67x	1.64x	1.63x	1.85x
Quick ratio	1.00x	1.03x	0.97x	1.04x	1.24x
Leverage
D/E	0.32x	0.30x	0.36x	0.42x	0.37x
Interest coverage	16.33x	12.21x	10.17x	14.99x	15.81x
Efficiency
Asset turnover	0.51x	0.52x	0.55x	0.59x	0.57x
Cash conversion cycle	+108d	+99d	+106d	+82d	+70d

Valuation

Price against fundamentals

ABT $133 · 2025-09-29 · 351d old · FY2025

Market cap $232.7B

P/E 35.66x

P/S 5.25x

P/B 4.46x

EV $237.1B

EV/EBITDA 24.35x

FCF yield +3.2%

Dividend yield +1.8%

Notes

Your annotations

Not watched

Abbott Laboratories

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history